Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 4, 2013, Pages 332-338

  Jiang, Rongrong ^a   Yamaori, Satoshi ^a   Okamoto, Yasuka ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cannabidiol; CYP2C19; Inhibition; Structural requirement

Indexed keywords

4' HYDROXYMEPHENYTOIN; CANNABIDIOL; CYTOCHROME P450 2C19; OMEPRAZOLE;

ARTICLE; CONCENTRATION RESPONSE; DEMETHYLATION; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; NONHUMAN;

ARYL HYDROCARBON HYDROXYLASES; CANNABIDIOL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MICROSOMES, LIVER; OMEPRAZOLE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880409258     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-129     Document Type: Article

References (49)

1. Mechoulam, R., Parker, L. and Gallily, R.: Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol., 42: 11-19 (2002).
2. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horváth, B., Mukhopadhyay, B., Becker, L., Haskó, G., Liaudet, L., Wink, D. A., Veves, A., Mechoulam, R. and Pacher, P.: Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol., 56: 2115-2125 (2010).
3. Lim, M., Devi, L. and Rozenfeld, R.: Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis., 2: e170 (2011).
4. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J. and Ambler, Z.: A double-blind, randomized, placebocontrolled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res., 32: 451-459 (2010).
5. Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G. and Flowler, C. J.: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. J., 16: 1349-1359 (2010).
6. Selvarajah, D., Gandhi, R., Emery, C. J. and Tesfaye, S.: Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal produce (Sativex) in painful diabetic neuropathy. Diabetes Care, 33: 128-130 (2010).
7. Wade, D. T., Collin, C., Stott, C. and Duncombe, P.: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. J., 16: 707-714 (2010).
8. Martin, B. R., Harvey, D. J. and Paton, W. D.: Biotransformation of cannabidiol in mice. Identification of new acid metabolites. Drug Metab. Dispos., 5: 259-267 (1977).
9. Harvey, D. J. and Mechoulam, R.: Metabolites of cannabidiol identified in human urine. Xenobiotica, 20: 303-320 (1990).
10. Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I. and Watanabe, K.: Identification of cytochrome P450 enzymes responsible for cannabidiol by human liver microsomes. Life Sci., 89: 165-170 (2011).
11. Wrighton, S. A., Stevens, J. C., Becker, G. W. and Vandenbranden, M.: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and (S)-mephenytoin 4A-hydroxylation. Arch. Biochem. Biophys., 306: 240-245 (1993).
12. Karam, W. G., Goldstein, J. A., Lasker, J. M. and Ghanayem, B. I.: Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos., 24: 1081-1087 (1996).
13. Pearce, R. E., Rodrigues, A. D., Goldstein, J. A. and Parkinson, A.: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther., 277: 805-816 (1996).
14. Bajpai, M., Roskos, L. K., Shen, D. D. and Levy, R. H.: Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos., 24: 1401-1403 (1996).
15. m diazepam N-demethylases. Drug Metab. Dispos., 25: 133-139 (1997).
16. von Moltke, L. L., Greenblatt, D. J., Giancarlo, G. M., Granda, B. W., Harmatz, J. S. and Shader, R. I.: Escitalopram (s-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to r-citalopram. Drug Metab. Dispos., 29: 1102-1109 (2001).
17. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihana, K., Fraid, N. A., Okazaki, O., Ikeda, T. and Kurihara, A.: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogerol to its pharmacologically active metabolite. Drug Metab. Dispos., 38: 92-99 (2010).
18. Hulot, J., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C., Aiach, M., Lechat, P. and Gaussen, P.: Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108: 2244-2247 (2006).
19. Brandt, J., Close, S., Iturria, J., Payne, C., Farid, N., Ernest, C., Lachno, D., Salazar, D. and Winters, K.: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamics response to clopidogrel but not prasugrel. J. Thromb. Haemost., 5: 2429-2436 (2007).
20. 1-tetrahydrocannabinol. Br. J. Pharmacol., 45: 375-377 (1972).
21. Benowitz, N. L., Nguyen, T., Jones, R. T., Herning, R. I. and Bachman, J.: Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin. Pharmacol. Ther., 28: 115-120 (1980).
22. Jaeger, W., Benet, L. Z. and Bornheim, L. M.: Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica, 26: 275-284 (1996).
23. Yamaori, S., Kushihara, M., Yamamoto, I. and Watanabe, K.: Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem. Pharmacol., 79: 1691-1698 (2010).
24. Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I. and Watanabe, K.: Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci., 88: 730-736 (2011).
25. Yamaori, S., Maeda, C., Yamamoto, I. and Watanabe, K.: Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol., 29: 117-124 (2011).
26. Yamaori, S., Okamoto, Y., Yamamoto, I. and Watanabe, K.: Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab. Dispos., 39: 2049-2056 (2011).
27. Yamaori, S., Koeda, K., Kushihara, M., Hada, Y., Yamamoto, I. and Watanabe, K.: Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab. Pharmacokinet., 27: 294-300 (2012).
28. Aramaki, H., Tomiyasu, N., Yoshimura, H. and Tsukamoto, H.: Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem. Pharm. Bull. (Tokyo), 16: 822-826 (1968).
29. Gohda, H., Narimatsu, S., Yamamoto, I. and Yoshimura, H.: In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol. Chem. Pharm. Bull. (Tokyo), 38: 1697-1701 (1990).
30. Watanabe, K., Arai, M., Narimatsu, S., Yamamoto, I. and Yoshimura, H.: Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem. Pharmacol., 36: 3371-3377 (1987).
31. Chiba, K., Manabe, K., Kobayashi, K., Takayama, Y., Tani, M. and Ishizaki, T.: Development and preliminary application of a simple assay of (S)-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur. J. Clin. Pharmacol., 44: 559-562 (1993).
32. Sudsakorn, S., Skell, J., Williams, D. A., O'Shea, T. J. and Liu, H.: Evaluation of 3-O-Methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. Drug Metab. Dispos., 35: 841-847 (2007).
33. Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B. and Tremaine, L. M.: The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 316: 336-348 (2006).
34. Kanamitsu, S., Ito, K. and Sugiyama, Y.: Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res., 17: 336-343 (2000).
35. Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgward, S. J., Allen, P., Martin-Santos, R., Seal, M., et al.: Distinct effects of delta 9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry, 66: 95-105 (2009).
36. Grotenhermen, F.: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet., 42: 327-360 (2003).
37. 1)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos., 30: 235-239 (2002).
38. 1)-N-3-benzylphenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab. Dispos., 32: 584-586 (2004).
39. Li, X., Andersson, T. B., Ahlström, M. and Weidolf, L.: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos., 32: 821-827 (2004).
40. Foti, R. S. and Wahlstrom, J. L.: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab. Dispos., 36: 523-528 (2008).
41. 1)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab. Dispos., 30: 602-607 (2002).
42. Zuardi, A., Cosme, R., Graeff, F. and Guimaraes, F.: Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol., 7: 82-88 (1993).
43. Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuard, A. W. and Crippa, J. A. S.: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36: 1219-1226 (2011).
44. Zuardi, A., Crippa, J. and Hallak, J.: Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res., 39: 421-429 (2006).
45. Harvey, A. T. and Perskorn, S. H.: Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J. Clin. Psychopharmacol., 21: 161-166 (2001).
46. Thomas, B. F., Compton, D. R. and Martin, B. R.: Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther., 255: 624-630 (1990).
47. Consroe, P., Kennedy, K. and Schram, K.: Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav., 40: 517-522 (1991).
48. Klaassen, S. L.: Ticlopidine-induced phenytoin toxicity. Ann. Pharmacother., 32: 1295-1298 (1998).
49. Levy, R. H.: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia, 36: S8-S13 (1995).